Dasiglucagon + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperinsulinemic Hypoglycemia
Conditions
Hyperinsulinemic Hypoglycemia, Postprandial Hypoglycemia
Trial Timeline
Aug 20, 2021 → Dec 15, 2022
NCT ID
NCT04836273About Dasiglucagon + Placebo
Dasiglucagon + Placebo is a phase 2 stage product being developed by Zealand Pharma for Hyperinsulinemic Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04836273. Target conditions include Hyperinsulinemic Hypoglycemia, Postprandial Hypoglycemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04836273 | Phase 2 | Completed |
| NCT04172441 | Phase 2/3 | Completed |
| NCT03735225 | Phase 1 | Completed |
| NCT03688711 | Phase 3 | Completed |
Competing Products
2 competing products in Hyperinsulinemic Hypoglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pasireotide | Novartis | Phase 1 | 33 |
| Glucagon RTU | Xeris Pharmaceuticals | Phase 2 | 47 |